InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

Current share price for PAR : $0.180 0.005 (2.86%)+

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$108 PARADIGM RECEIVES KEY REGULATORY APPROVALS FOR MPS VI STUDY 18 Jun 2021 9:09AM $1.990 $0.180 fallen by 90.95%
$108 IND QUESTIONS RECEIVED FROM US FDA 25 May 2021 8:23AM $2.320 $0.180 fallen by 92.24%
$108 Cleansing Notice and Appendix 2A 21 May 2021 4:27PM $2.420 $0.180 fallen by 92.56%
$108 PARADIGM ACHIEVES FIRST REVENUE 19 May 2021 9:00AM $2.100 $0.180 fallen by 91.43%
$108 Cleansing Notice and Appendix 2A 13 May 2021 5:10PM $2.060 $0.180 fallen by 91.26%
$108 Paradigm to Present at Truist Securities Life Sciences Summi 3 May 2021 9:02AM $2.310 $0.180 fallen by 92.21%
$108 Quarterly Update and Appendix 4C - quarterly 30 Apr 2021 8:32AM $2.350 $0.180 fallen by 92.34%
$108 PARADIGM PROVIDES IND APPLICATION UPDATE 26 Apr 2021 9:02AM $2.550 $0.180 fallen by 92.94%
$108 Cleansing Notice and Appendix 2A 15 Apr 2021 4:25PM $2.550 $0.180 fallen by 92.94%
$108 Paradigm doses first participant in Synovial Fluid Trial 14 Apr 2021 9:16AM $2.570 $0.180 fallen by 93%
$108 Paradigm and Bene Execute New Collaboration Agreement 31 Mar 2021 8:31AM $2.610 $0.180 fallen by 93.10%
$108 Paradigm delivers IND to US FDA for Pivotal OA Program 26 Mar 2021 9:40AM $2.400 $0.180 fallen by 92.50%
$108 PHASE 2 RRV DATA PUBBLISHED IN PEER-REVIEWED JOURNAL 18 Mar 2021 9:05AM $2.510 $0.180 fallen by 92.83%
$108 Initial Director's Interest Notice 26 Feb 2021 4:31PM $2.400 $0.180 fallen by 92.50%
$108 Half Yearly Report and Accounts 24 Feb 2021 12:13PM $2.490 $0.180 fallen by 92.77%
$108 Paradigm Receives $3.38m R&D Tax Incentive Refund 23 Feb 2021 8:54AM $2.560 $0.180 fallen by 92.97%
$108 Ethics Approval Received for Synovial Fluid Biomarker Study 18 Feb 2021 10:49AM $2.600 $0.180 fallen by 93.08%
$108 Paradigm Welcomes Helen Fisher as Non-Executive Director 11 Feb 2021 8:55AM $2.750 $0.180 fallen by 93.45%
$108 Consistent pain reduction and improvement in function data 3 Feb 2021 8:18AM $2.490 $0.180 fallen by 92.77%
$108 Statement pursuant to Listing Rule 4.7C.3 1 Feb 2021 4:57PM $2.350 $0.180 fallen by 92.34%
$108 Quarterly Update and Appendix 4C - quarterly 29 Jan 2021 8:22AM $2.300 $0.180 fallen by 92.17%
$108 Response to ASX Query 21 Jan 2021 5:27PM $2.440 $0.180 fallen by 92.62%
$108 Change in substantial holding 18 Jan 2021 5:50PM $2.450 $0.180 fallen by 92.65%
$108 Change of Director's Interest Notice 18 Jan 2021 5:50PM $2.450 $0.180 fallen by 92.65%
$108 Change of Director's Interest Notice 18 Jan 2021 5:49PM $2.450 $0.180 fallen by 92.65%

376 - 400 of 721 results

Page 16 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.